- Home
- IMVT vs OGN Comparison
IMVT vs OGN Comparison
Compare IMVT & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMVT
- OGN
- Stock Information
- Founded
- IMVT 2018
- OGN 1923
- Country
- IMVT United States
- OGN United States
- Employees
- IMVT N/A
- OGN N/A
- Industry
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- IMVT Health Care
- OGN Health Care
- Exchange
- IMVT Nasdaq
- OGN Nasdaq
- Market Cap
- IMVT 2.8B
- OGN 2.5B
- IPO Year
- IMVT N/A
- OGN N/A
- Fundamental
- Price
- IMVT $16.95
- OGN $9.96
- Analyst Decision
- IMVT Buy
- OGN Hold
- Analyst Count
- IMVT 10
- OGN 4
- Target Price
- IMVT $40.14
- OGN $18.00
- AVG Volume (30 Days)
- IMVT 1.4M
- OGN 4.0M
- Earning Date
- IMVT 08-05-2025
- OGN 08-05-2025
- Dividend Yield
- IMVT N/A
- OGN 0.80%
- EPS Growth
- IMVT N/A
- OGN N/A
- EPS
- IMVT N/A
- OGN 2.88
- Revenue
- IMVT N/A
- OGN $6,294,000,000.00
- Revenue This Year
- IMVT N/A
- OGN N/A
- Revenue Next Year
- IMVT N/A
- OGN $1.11
- P/E Ratio
- IMVT N/A
- OGN $3.46
- Revenue Growth
- IMVT N/A
- OGN N/A
- 52 Week Low
- IMVT $12.72
- OGN $8.01
- 52 Week High
- IMVT $34.47
- OGN $23.10
- Technical
- Relative Strength Index (RSI)
- IMVT 60.86
- OGN 51.96
- Support Level
- IMVT $15.80
- OGN $9.55
- Resistance Level
- IMVT $17.06
- OGN $10.44
- Average True Range (ATR)
- IMVT 0.68
- OGN 0.36
- MACD
- IMVT 0.07
- OGN 0.03
- Stochastic Oscillator
- IMVT 86.70
- OGN 51.52
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.